Latest Regulatory News

Mt Malcolm Mines NL has taken a major step forward with the acquisition of a 500,000 tonnes per annum gold processing plant and an oversubscribed $3.05 million capital raise, while drilling at Picnic South confirms consistent near-surface gold mineralisation.

Paradigm Biopharmaceuticals has secured independent validation of its Phase 2 iPPS biomarker study, published in a leading rheumatology journal, reinforcing the scientific basis for its Phase 3 osteoarthritis trial.

Audalia Resources is progressing its Medcalf vanadium-titanium-iron project with an updated Pre-feasibility Study and fresh capital injection, positioning the company for its maiden ore reserve announcement.

St Barbara Limited reports strong feasibility outcomes for its New Simberi Gold Project and Nova Scotia developments, backed by significant strategic investments and regulatory approvals.

Siren Gold Limited has advanced its New Zealand gold and antimony projects with a major drilling campaign at Sams Creek and promising exploration results at Queen Charlotte, while navigating regulatory hurdles.

Atomo Diagnostics reported a robust 121% quarter-on-quarter revenue increase to $1.5 million, driven by new orders for its FebriDx Pascal and HIV Self-Test products. The company also secured a global licensing deal for a novel liver function test and expanded manufacturing capacity to support growing demand.

Bank of Queensland has appointed Rod Finch as its new CEO, marking a leadership transition aimed at continuing its strategic transformation and operational improvements.

Toubani Resources has landed a credit-approved term sheet from Coris Bank for more than US$80 million in project financing, marking a significant step forward for its Kobada Gold Project in Mali.

Tasman Resources reports a robust cash position and a valuable stake in Eden Innovations, while gearing up for significant drilling programs at its South Australian projects in 2026.

Element 25 Limited has made significant strides in advancing its Butcherbird Expansion Project in Western Australia, securing $60 million in funding and progressing key engineering and contract milestones. Simultaneously, the company moves closer to finalising financing for its US-based battery-grade manganese refinery.

Chimeric Therapeutics reports encouraging clinical progress in its CAR-T and NK cell therapy trials, alongside FDA orphan drug designation and a strategic funding boost to propel development.

Meteoric Resources has cleared a major regulatory hurdle with the approval of its Preliminary Environmental License for the Caldeira Rare Earths Project, enabling the company to progress towards construction and first production targeted for 2028. The company also commissioned its pilot plant, producing its first batches of rare earth carbonate.